Literature DB >> 25909238

Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.

Marc Schargus1, Svetlana Ivanova, Vinodh Kakkassery, H Burkhard Dick, Stephanie Joachim.   

Abstract

PURPOSE: Given that early-stage dry eye is difficult to diagnose, the purpose of this study was to evaluate the performance of matrix metalloproteinase 9 (MMP-9) and tear film osmolarity (TFO) in a cohort of elderly patients with potential dry eye disease (DED).
METHODS: A group of 20 patients, aged 60 years and above, previously undiagnosed with DED were selected. The following DED tests were performed: tear osmolarity, MMP-9 (InflammaDry), Schirmer test, tear film break-up time, Ocular Surface Disease Index (OSDI) questionnaire, corneal fluorescein staining, and conjunctival lissamine green staining. MMP-9 concentrations in tears collected through Schirmer strips were analyzed by an MMP-9 enzyme-linked immunosorbent assay [ELISA]. Subjects were classified by symptoms (classification A: OSDI ≥10, n = 9), based on suspected mild dry eye (classification B: n = 14), TFO difference >8 mOsm/L between both eyes (classification C: n = 13), and TFO cutoff at 308 mOsm/L (classification D: >308 mOsm/L, n = 11).
RESULTS: Eleven percent (1/9) of the symptomatic and 14% (2/14) of the suspected mild dry eye were positive for MMP-9. InflammaDry MMP-9 tests were confirmed to be accurate through an ELISA. Sixty-seven percent (6/9) of the symptomatic and 64% (9/14) of the suspected mild dry eye were positive for tear osmolarity. None of the evaluated tear film parameters showed a significant correlation, although tear osmolarity and symptoms trended toward significance (r = 0.433, P = 0.06), whereas MMP-9 and corneal staining showed a positive association (r = 0.376, P = 0.10).
CONCLUSIONS: Similar to corneal staining, the MMP-9 is likely a late-stage sign that is rarely overexpressed in mild subjects, whereas tear osmolarity tends to be a more frequent early indicator of ocular surface disequilibrium within mild subjects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25909238     DOI: 10.1097/ICO.0000000000000449

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  21 in total

Review 1.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 2.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

Review 3.  [Diagnosis and treatment of the watering eye].

Authors:  M Schargus; G Geerling
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

Review 4.  The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.

Authors:  Nicole L Lanza; Felipe Valenzuela; Victor L Perez; Anat Galor
Journal:  Ocul Surf       Date:  2016-02-02       Impact factor: 5.033

Review 5.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

Review 6.  Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.

Authors:  Charles P Semba; Thomas R Gadek
Journal:  Clin Ophthalmol       Date:  2016-06-10

Review 7.  Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.

Authors:  Christophe Baudouin; Murat Irkeç; Elisabeth M Messmer; José M Benítez-Del-Castillo; Stefano Bonini; Francisco C Figueiredo; Gerd Geerling; Marc Labetoulle; Michael Lemp; Maurizio Rolando; Gysbert Van Setten; Pasquale Aragona
Journal:  Acta Ophthalmol       Date:  2017-04-08       Impact factor: 3.761

8.  Aged Mice Devoid of the M3 Muscarinic Acetylcholine Receptor Develop Mild Dry Eye Disease.

Authors:  Aytan Musayeva; Subao Jiang; Yue Ruan; Jenia Kouchek Zadeh; Panagiotis Chronopoulos; Norbert Pfeiffer; Werner E G Müller; Maximilian Ackermann; Ning Xia; Huige Li; Adrian Gericke
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

9.  Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes.

Authors:  Alice T Epitropoulos; Eric D Donnenfeld; Zubin A Shah; Edward J Holland; Michael Gross; William J Faulkner; Cynthia Matossian; Stephen S Lane; Melissa Toyos; Frank A Bucci; Henry D Perry
Journal:  Cornea       Date:  2016-09       Impact factor: 2.651

Review 10.  Review: The Lacrimal Gland and Its Role in Dry Eye.

Authors:  Christopher D Conrady; Zachary P Joos; Bhupendra C K Patel
Journal:  J Ophthalmol       Date:  2016-03-02       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.